Factor V Leiden Management

Introduction to Risk Factors

• Combined oral contraceptives increase thrombotic risk 30-fold in Factor V Leiden carriers compared to 4-fold in non-carriers, particularly in young women with Factor V Leiden, increasing myocardial infarction risk 32-fold 1
• Smoking is particularly dangerous in young women (<45 years) with Factor V Leiden, increasing myocardial infarction risk 32-fold 1

Anticoagulation and Prophylaxis

• Consider prophylactic anticoagulation during high-risk situations, such as pregnancy and postpartum period, in women with Factor V Leiden, as recommended by the American College of Chest Physicians 1, 2
• For women with Factor V Leiden and family history of VTE, prophylactic anticoagulation is recommended for 6 weeks postpartum to reduce the risk of VTE 1, 2
• Low molecular weight heparin (LMWH) is preferred over warfarin during pregnancy due to the risks associated with warfarin use in pregnant women 2

Contraception and Hormone Replacement Therapy

• Avoid estrogen-containing contraceptives in women with Factor V Leiden, as they synergistically increase thrombotic risk, according to guidelines from relevant medical societies 1
• Alternative contraceptive methods should be offered to women with Factor V Leiden, and estrogen-containing medications should be avoided, as recommended by the American Heart Association 1

Testing and Screening

• Testing for Factor V Leiden is recommended in patients with VTE before age 50, VTE in unusual sites, recurrent VTE, VTE with strong family history of thrombotic disease, VTE during pregnancy or oral contraceptive use, relatives of individuals with VTE under age 50, and women with recurrent pregnancy loss or severe pregnancy complications 1
• The following tests are essential for diagnosis and management: complete blood count (CBC) with platelets, coagulation studies (prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR) if transitioning from or to warfarin), and renal function tests (serum creatinine, blood urea nitrogen (BUN), and creatinine clearance) 2, 3, 4

Patient Management

• Regular INR monitoring is necessary to maintain target range of 2.0-3.0 for warfarin therapy in patients with Factor V Leiden requiring anticoagulation, as recommended by the American College of Chest Physicians 1, 2, 5
• Anti-Factor Xa levels should be monitored for LMWH therapy, with target ranges of 0.2-0.6 U/mL for prophylactic dosing and 0.7-1.2 U/mL for therapeutic dosing, as recommended by the American College of Cardiology 2, 3
• Assessing thrombotic risk is critical, and the presence of additional risk factors such as other thrombophilias, history of previous VTE, immobility, recent surgery, active malignancy, estrogen-containing medications, or pregnancy/postpartum state should be considered 2
• Patients should be advised to manage modifiable risk factors, such as smoking cessation, weight management, and avoiding estrogen-containing medications, to reduce their overall thrombotic risk, as recommended by the American College of Chest Physicians 2

Comparison of Factor V Deficiency and Factor V Leiden

Special Considerations

• No long-term anticoagulation is recommended for asymptomatic carriers, but consider prophylactic anticoagulation in high-risk situations such as major surgery, prolonged immobilization, or pregnancy, as suggested by the American College of Obstetricians and Gynecologists 1
• Routine anticoagulation for asymptomatic heterozygotes is not recommended due to the risk of bleeding outweighing the benefits, according to guidelines from thrombosis and hemostasis societies 1
• Homozygotes have a substantially higher thrombosis risk and may benefit from more aggressive prophylaxis, as indicated by guidelines from relevant medical societies 1